

**Supplementary Material Table 2**  
**Hierarchical(note), multivariate epoch analysis of the follow-up change**  
**in EQ-5D tariff score in the SOHO study with 36-month study completers**  
**only**

Change in EQ-5D score for each epoch duration							
Variable (reference category)	Category	6	12	18	24	30	36
Sex (Female)	Male	-0.006	-0.007	-0.008	-0.005	-0.014	-0.009
Duration of illness (< 1 year)	1 to 5	0.001	-0.004	0.005	-0.012	-0.005	-0.004
	5 to 10	-0.019	-0.018	-0.013	-0.014	-0.029*	-0.028
	10 to 20	-0.012	-0.020	-0.013	-0.019	-0.025	-0.017
	20+	-0.054**	-0.066**	-0.053**	-0.073**	-0.075**	-0.089**
Age at first contact for treatment (<20 years)	20 to 25	0.006	-0.004	-0.008	-0.015	-0.016	-0.007
	25 to 30	-0.015	-0.025*	-0.016	-0.040**	-0.021	-0.023
	30 to 35	-0.005	-0.011	-0.021	-0.045**	-0.016	-0.017
	35+	-0.014	-0.041**	-0.054**	-0.050**	-0.041**	-0.056**
BMI (Under & Normal)	Obese	0.001	-0.002	-0.007	-0.014	-0.002	0.009
	Overweight	-0.007	0.015*	0.003	0.007	0.011	0.012
Spouse (no)	Yes	-0.003	0.003	0.003	0.012	0.022*	0.008
Independent housing (no)	Yes	0.006	0.010	0.008	0.017	0.002	0.034**
Paid employment (no)	Yes	0.033**	0.023*	0.011	0.013	0.025*	0.025*
Number of social activities (0 activities)	1 to 4	0.024**	0.022**	0.013	0.017	-0.006	0.016
	5+	0.021*	0.019	0.028*	0.013	0.001	0.012
Previous PO typical use (no)	Yes	0.001	0.009	-0.008	0.004	0.007	0.006
Previous depot typical use (no)	Yes	0.005	-0.011	-0.017	-0.010	0.001	-0.030*
Previous clozapine use (no)	Yes	-0.035	-0.056**	-0.042	-0.072**	-0.036	-0.047
Previous olanzapine use (no)	Yes	-0.001	-0.005	-0.014	0.003	-0.008	-0.002
Previous risperidone use (no)	Yes	-0.012	-0.006	-0.019	-0.008	-0.008	-0.008
Previous other atypical use (no)	Yes	-0.009	-0.013	-0.008	-0.001	0.009	0.006
First episode (no)	Yes	-0.011	-0.001	-0.012	-0.004	-0.010	-0.001
Anticholinergics use (no)	Yes	-0.001	0.010	-0.002	0.017	0.022	0.025
Antidepressant use (no)	Yes	-0.015	-0.041**	-0.024*	-0.016	-0.020	-0.027
Anxiolytics/Hypnotic use (no)	Yes	0.002	-0.011	0.004	0.008	0.017	0.012
Mood Stabilizer use (no)	Yes	-0.004	-0.013	-0.008	-0.010	-0.004	0.004
Any concomitant (no)	Yes	-0.001	-0.008	0.012	0.012	0.025	0.002
Positive CGI	NA	0.001	-0.001	0.001	0.004	-0.001	0.008
Negative CGI	NA	-0.002	-0.002	-0.001	0.000	0.004	0.010*
Depressive CGI	NA	0.001	0.006	0.005	0.005	0.007	0.007
Cognitive CGI	NA	-0.003	-0.003	0.000	0.004	-0.003	-0.001
Overall CGI (1 to 2)	3	0.003	-0.017	0.009	0.009	-0.014	-0.026
	4	-0.004	-0.012	0.013	0.000	-0.013	-0.040*
	5	0.001	-0.016	0.024	0.023	0.026	-0.019
	6 to 7	0.074*	0.088*	0.004	0.034	0.122**	0.111*
EPS (no)	Yes	0.013	0.004	-0.001	0.001	-0.008	-0.004
TD (no)	Yes	-0.023	-0.024	0.001	-0.003	-0.016	-0.018
Jail (no)	Yes	0.020	0.018	0.016	0.052**	0.022	0.028
Substance abuse (no)	Yes	-0.005	0.002	0.004	-0.006	0.023	0.008

Alcohol dependency (no)	Yes	-0.040*	-0.003	-0.022	-0.032	-0.038	-0.068
Hostile (no)	Yes	-0.002	-0.011	-0.004	-0.012	-0.003	-0.009
Suicide attempts (no)	Yes	-0.019	-0.007	-0.022	0.000	-0.011	0.018
Baseline EQ-5D score	1 Quartile	0.498**	0.547**	0.564**	0.575**	0.593**	0.623**
(4 Quartile Base EQ-5D score)	2 Quartile	0.150**	0.197**	0.207**	0.203**	0.249**	0.282**
	3 Quartile	0.074**	0.084**	0.089**	0.091**	0.113**	0.105**
Treatment (Olanzapine)	Amisulpride	-0.030	-0.033	-0.037	-0.049*	-0.040	-0.044
	Clozapine	0.013	-0.001	-0.013	-0.005	0.012	0.019
	Depot Typical	-0.065**	-0.073**	-0.059**	-0.054**	-0.050**	-0.090**
	PO Typical	-0.089**	-0.084**	-0.080**	-0.081**	-0.078**	-0.085**
	Quetiapine	-0.044**	-0.042**	-0.043**	-0.046**	-0.067**	-0.031
	Risperidone	-0.038**	-0.045**	-0.038**	-0.033**	-0.034**	-0.019

\* 0.05 > p > 0.01; \*\* p < 0.01 versus reference category

FOOTNOTE: The participating investigator has been considered a random effect.

BMI categories: Under and normal (<25 kg/m<sup>2</sup>), overweight (25-30 kg/m<sup>2</sup>) and obese (>30 kg/m<sup>2</sup>)